Seer’s stock jumped in July as the company became the target of competing takeover bids, prompting additional investor-driven offers and board resistance. GenomeWeb reporting highlighted a 34% month-over-month rise for Seer, largely tied to “dueling takeover bids” from Seer investors and CEO Omid Farokhzad. The sequence began with an offer to acquire all outstanding Class A shares for $2.45 per share plus contingent value rights, followed by a higher bid of $2.55 per share plus contingent value rights. Seer’s board rejected the offers so far, leaving the outcome tied to negotiation dynamics and the company’s assessment of value. The episode also illustrates how proteomics valuations can swing on acquisition probability, even without new clinical readouts—particularly in markets where platform companies seek scale through consolidation.